Johnson Pharma (532154)
Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹1.14 |
| Market Cap | ₹63.25 Cr |
| P/E Ratio | 0 |
| ROCE | -0.43% |
| ROE | -1.12% |
| Dividend Yield | 0% |
| Profit Growth | -100% |
| Debt/Equity | — |
| Sales Growth | 0% |
| 52-Week Range | ₹0.47 — ₹1.14 |
| Sector | Commercial Services & Supplies |
| Book Value | ₹1.06 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
Let me look at Johnson Pharma the way I would any business. First, what does it earn? Nothing. Latest quarter sales are ₹0 Cr, net profit is ₹-0 Cr, and profit growth is -100%. The P/E of 0.00 is not a bargain signal; it is an accounting artifact when earnings are absent. Return on equity is -1.12% and ROCE is -0.43%, so this enterprise is destroying value, not compounding it. The Piotroski F-Score of 2/9 reinforces that: the financial health is poor.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer